Any content you receive is for information purposes only. Always conduct your own research. |
*Disseminated on Behalf of Medicus Pharma Ltd. |
Don’t miss the next breakout — get real-time alerts sent straight to your phone! |
An 80% ORR, Capitol Hill Meetings, and a ~$8B Pipeline — Why (NASDAQ: MDCX) Just Landed on Our Radar and Will be Topping Today’s Watchlist |
—Thursday, May 28th, 2026 |
|
May 28, 2026 |
Dear Reader, |
You don't see this combination every day — Phase 2 data, an FDA orphan dr-ug filing, Capitol Hill meetings, and a ~$8B dual-asset pipeline. |
That's Medicus Pharma Ltd. (NASDAQ: MDCX), and it just earned a spot at the top of this morning’s watchlist. |
The company recently disclosed that CEO Dr. Raza Bokhari and Medicus leadership met with senior members of the House Energy & Commerce Committee on Capitol Hill to advance support for Orphan Dr-ug designation, a registrational IND pathway, and rare-disease pediatric voucher access for SkinJect® in Gorlin Syndrome. |
This is a rare genetic disorder with zero approved therapies — and Medicus is actively pushing for a fast-tracked regulatory path. |
That level of congressional engagement from a small-cap biotech could be a sign that leadership is setting the stage for something much bigger. |
Here's why we're shining a spotlight on (MDCX) right now. |
The global basal cell carcinoma treatment market — the exact arena where Medicus competes — is expected to nearly double to $5.93B by 2030, expanding at a 10.4% CAGR, according to Grand View Research. |
Medicus is planting its flag right at the center of that growth with a non-surgical approach that could fundamentally change how skin cancer gets treated. |
Medicus Pharma Ltd. (NASDAQ: MDCX) sits at the top of our watchlist today—Thursday, May 28th 2026. |
Here's what the company does — and why their science deserves your attention. |
Medicus Pharma is a precision-guided biotech dedicated to accelerating clinical development of novel therapeutics across multiple countries and three continents. |
Their flagship asset, SkinJect® (D-MNA), is a patented dissolvable microneedle array engineered for direct intradermal delivery of doxorubicin into basal cell carcinoma lesions. |
The microneedles penetrate the skin, dissolve on contact, and release the dr-ug locally — enabling direct tumor cell destruction and local immune activation. |
It's targeted, repeatable, and built to help patients skip the surgeon's blade. |
The company's second major asset is Teverelix®, a next-generation long-acting injectable GnRH antagonist acquired through Antev Limited (UK). |
Teverelix® is positioned as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and those suffering from acute urinary retention relapse — together representing a ~$6B addressable market, according to the company. |
Combined, these two assets hand Medicus a dual-pipeline aimed at ~$8B in total market scope. |
|
|
A Pipeline Loaded With Potential Catalysts |
Orphan Dr-ug Designation filed with the FDA — The company stated, submitted an ODD application for SkinJect® in Gorlin Syndrome, targeting a rare condition affecting ~11,000 U.S. patients with no currently approved therapies. If granted, this could unlock 7 years of market exclusivity along with potential tax credits. |
Teverelix Phase 2 study submitted to FDA — The company also stated, they submitted an optimized Phase 2 design for Teverelix® in acute urinary retention relapse — a ~$2B target market with no approved pharmacologic therapies. The streamlined ~126-patient design could deliver an early pharmacodynamic signal within ~12 weeks. |
KOL validation of 80% overall response rate — According to the company's press release, independent key opinion leaders confirmed an 80% ORR from Phase 2 SkinJect® data, with 73% clinical clearance in the 200-µg cohort. The company is now targeting an End-of-Phase 2 FDA meeting in the first half of 2026. |
Congressional advocacy on Capitol Hill — According to the April 27 press release, CEO Dr. Bokhari met with the Chair of the House Energy & Commerce Committee and members of the Congressional Skin Cancer Caucus to advance regulatory support. |
Teverelix® data presented at AACE 2026 — According to the company's press release, Phase 1 data demonstrated long-acting hormone suppression in premenopausal women, with dose-dependent estradiol suppression and favorable safety — supporting potential expansion into women's health indications like endometriosis. |
Q1 2026 Financials & Corporate Update — On May 14, 2026, Medicus reported Q1 results. Key highlights from the quarter include: |
Cash and cash equivalents of $6.4M as of March 31, 2026 (up from $4.0M a year prior) ~$10M raised through its ATM facility and SEPA during the quarter ATM facility expanded from ~$15.3M to up to $50M subsequent to quarter end FDA provided "study may proceed" clearance for the Phase 2b dose optimization study of Teverelix® in advanced prostate cancer Completed enrollment of 90 patients in the U.S.-based Phase 2 SKNJCT-003 study LifeArc licensing agreement amended — royalty rate on worldwide net sales reduced from ~4% to 2% Continued development of AI-enabled clinical capabilities through its collaboration with Reliant AI
|
CEO Dr. Raza Bokhari commented that the growing strength of their clinical datasets, combined with expanded financing flexibility and AI-enabled clinical capabilities, positions Medicus to pursue multiple value-driving milestones throughout 2026 and beyond. |
The clinical pipeline is advancing — but the market tailwind behind it paints an equally compelling picture. |
A Massive Market Shift |
According to Grand View Research, the BCC treatment market is on a steep growth curve — fueled by rising skin cancer incidence and the shift toward minimally invasive therapies. North America captured roughly 60% of the global market in 2023. |
BCC Treatment Market: $2.96B (2023) → $5.93B by 2030 at a 10.4% CAGR |
Intralesional Injections: The fastest-growing BCC treatment modality projected through 2033, driven by demand for non-surgical alternatives |
Non-Surgical / Minimally Invasive Therapies: Expanding rapidly as photodynamic therapy, microneedle arrays, and targeted immunotherapies gain ground against traditional surgical excision |
Here's what makes this relevant — SkinJect® fits directly into that fastest-growing intralesional injection segment. |
Medicus isn't chasing a trend. They're building exactly the product this market is already calling for. |
With all of that laid out, here's the condensed case for why this name deserves your attention right now. |
|
|
8 Reasons Why (MDCX) Is On Our Radar |
1. Phase 2 clinical data that stands apart — SkinJect® delivered 73% clinical clearance and 80% overall response rate validated by independent KOL review, suggesting roughly 3 out of 4 treated lesions could help patients sidestep immediate surgical intervention in a ~$2B BCC market. |
2. Orphan Dr-ug Designation pending with the FDA — The ODD application for SkinJect® in Gorlin Syndrome targets a rare genetic condition with ~11,000 U.S. patients and no approved therapies — and if granted, could provide 7 years of market exclusivity, tax credits, and fee waivers. |
3. Teverelix® Phase 2 pushing into a wide-open market — The optimized study design targets acute urinary retention relapse, a ~$2B space with no currently approved pharmacologic therapies, and could generate early pharmacodynamic data within ~12 weeks. |
4. Dual-asset pipeline spanning ~$8B in addressable markets — SkinJect® (~$2B in BCC/Gorlin Syndrome) and Teverelix® (~$6B in advanced prostate cancer with high CV risk and AURr) are both in Phase 2 — giving Medicus two shots on goal. |
5. Analyst coverage signals meaningful upside — D. Boral Capital maintains a bullish rating. |
6. Congressional engagement and regulatory momentum — Direct meetings with the Chair of the House Energy & Commerce Committee signal that Medicus is pursuing every channel to fast-track SkinJect® toward approval for Gorlin Syndrome patients. |
7. Microneedle platform optionality beyond oncology — The dissolvable microneedle delivery system is being explored for thermostable mRNA vaccine delivery through a non-binding MoU with HelixNano, representing potential platform expansion into infectious disease. |
8. Q1 2026 execution and strengthened balance sheet — The company raised ~$10M in Q1, expanded its ATM to $50M, secured FDA clearance to proceed with Teverelix® Phase 2b, and completed enrollment in the Phase 2 SkinJect® study — all while reducing future royalty obligations on Teverelix® from ~4% to 2%. |
Keep Your Eyes on MDCX... |
From Phase 2 SkinJect® data showing an 80% overall response rate, to a pending Orphan Dr-ug Designation, to Teverelix® advancing into a $2B unaddressed market, to direct congressional advocacy on Capitol Hill — (MDCX) is stacking potential catalysts at a pace that doesn't match its current value. |
Add in a dual-asset pipeline targeting ~$8B in combined market scope, a freshly expanded $50M ATM facility, and a Q1 showing that demonstrates execution across the board — and you can see why this name has a lot lined up. |
We have all eyes on (MDCX) today—Thursday, May 28th, 2026. |
|
Sincerely, |
Ryan Stryker
Senior Editor
Alpha Wire Daily |
|
AlphaWireDaily.com (“AlphaWireDaily” or “AWD” ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and AWD is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile AWD brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. |
Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 05/28/2026 and ending on 05/28/2026 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, GG Media Holdings LLC has been paid fifty nine thousand five hundred USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. |
Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (MDCX:US). |
Please see important disclosure information here: https://alphawiredaily.com/disclosure/mdcx-yN8je/#details |
No comments:
Post a Comment